Last reviewed · How we verify
NCT05207631: MIPIF
Intervention to Reduce Misused Inhaler and Insufficient Peak Inspiratory Flow in Hospitalized COPD Patients
NA trial testing Systematic and standardised assessment of inhalers and implementation of a prescribing guide in COPD in 101 participants. Completed in 24 January 2023.
25 December 2022
Quick facts
| Lead sponsor | Hôpital Fribourgeois |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 101 |
| Start date | 1 March 2022 |
| Primary completion | 25 December 2022 |
| Estimated completion | 24 January 2023 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Systematic and standardised assessment of inhalers and implementation of a prescribing guide
Conditions studied
- COPD — all drugs for COPD →
Sponsor
Hôpital Fribourgeois — full company profile →
Who can join
18 and older, any sex, with COPD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The drug treatment of chronic obstructive pulmonary disease (COPD) is mainly based on inhaled therapy. This route of administration is limited by inhaler handling errors, insufficient inspiratory flow or inappropriate inhalers. According to the scientific literature, these limitations are extremely common in both outpatients and inpatients. Our hypothesis is that the implementation of a standardised and systematic assessment of inhalers combined with a prescribing guide to help select a suitable inhaler will decrease the proportion of suboptimally used inhalers at discharge in patients hospitalised with a diagnosis of COPD. To assess the effectiveness of our intervention, the investigators will compare the proportion of inhalers used suboptimally at hospital discharge between a control cohort before the implementation of our intervention and a cohort after the implementation of our intervention. Secondary outcomes include reasons for sub-optimal use of inhalers, i.e. inhaler handling errors, insufficient peak inspiratory flow or inappropriate inhaler. Secondary outcomes will also include length of hospital stay and 30-day readmission rate.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
An in-hospital intervention to reduce the proportion of misused inhalers at hospital discharge among patients with COPD: a non-randomised intervention study.
Grandmaison G, Grobéty T, Dumont P, Vaucher J, et al · · 2024 · cited 2× · PMID 38579300 · DOI 10.57187/s.3394
Verify or expand the search:
- PubMed search for NCT05207631
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COPD
Currently open trials in the same condition.
- NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
- NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
- NCT07460154 — Structured Review: To Optimise Management and Prevent Harm in COPD · NA · recruiting
- NCT07462221 — Effect of Telenursing on Oral Health · NA · recruiting
- NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
Other Hôpital Fribourgeois trials
Trials by the same sponsor.
- NCT07477327 — Is 6 Weeks Immobilization for a Chopart Injury Still State of the Art? Comparison Between Cast Immobilization Versus Fun · NA · not yet recruiting
- NCT07264140 — Assessing and Improving Misuse of Inhalers in COPD Outpatients · NA · not yet recruiting
- NCT07346131 — ELUDYN: Assessment of Intra-individual Variability of Vascular Dynamics of Gadopiclenol Injection Parameters in Contrast · Phase 4 · recruiting
- NCT06971419 — FOllow-up of LOW-acuity Patients After REdirection From a Swiss Emergency Department Using an Electronic TRIage Applicat · not yet recruiting
- NCT06762561 — Prophylactic Mesh Reinforcement After Open Aortic Aneurysm Repair · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05207631 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hôpital Fribourgeois
- Last refreshed: 26 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05207631.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing